Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines ... PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, neurological & neuropsychological disorders, among others. It operates in following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of society's healthcare needs. 詳細を表示
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the...
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today...
Financing led by General Atlantic with participation from other top tier investors Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric...
IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for IPF Clinical abstract reviews the ability of...
Three presentations inform clinical, commercial and patient engagement strategies for LYT-100 for the treatment of idiopathic pulmonary fibrosis (IPF) Topline data from the Phase 2b ELEVATE IPF...
Milestone triggers payments to PureTech totaling $29 million under agreements with Royalty Pharma and PureTech’s Founded Entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb in...
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
Strong progress across PureTech’s portfolio, with significant near-term catalysts Robust shareholder returns enabled by Founded Entity1 monetization; $100 million Tender Offer and $50 million...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
quester614
16分前
MeteoricMonk73
17分前
MeteoricMonk73
17分前
MeteoricMonk73
18分前
MeteoricMonk73
18分前
MeteoricMonk73
20分前
MeteoricMonk73
20分前
MeteoricMonk73
20分前
MeteoricMonk73
20分前
MeteoricMonk73
22分前
MeteoricMonk73
22分前
MeteoricMonk73
23分前
MeteoricMonk73
23分前
MeteoricMonk73
23分前
MeteoricMonk73
23分前
MeteoricMonk73
24分前
LVerstee
26分前
Evaluate
29分前
joev2
35分前
sam1933
38分前
MGO 51
40分前
MiamiGent
43分前
eagle8
44分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
